Prescribing Paliperidone (Invega)

Why Paliperidone Matters

Paliperidone is risperidone's active metabolite, 9-hydroxyrisperidone, the molecule your patient's liver makes when you prescribe risperidone. Janssen isolated it, patented it, put it in an osmotic-release tablet, and launched it as Invega in December 2006, just as risperidone was going generic. The psychiatric press was unimpressed. In 2007 The Carlat Report put it bluntly: "Invega looks like Risperdal without drug-drug interactions, but with more QT interval prolongation, more tachycardia, possibly more EPS, and the same amount of hyperprolactinemia. Not a very pretty picture."

The skepticism was earned. Janssen never ran a head-to-head trial against risperidone, the parent drug sitting right there, and a Cochrane review had to conclude it was unable to determine whether paliperidone has any advantages or disadvantages compared to its well-known parent compound. Approval rested on placebo-controlled data. The oral tablet was, and largely remains, a patent-extension exercise.

It still deserves a place in your armamentarium, for three reasons that owe nothing to the marketing:

1. It bypasses the liver. Paliperidone is largely renally cleared (about 80% recovered in urine, roughly 59% of the dose excreted unchanged), with no single CYP450 pathway dominating its metabolism. That removes risperidone's biggest headache, the CYP2D6 interactions that swing risperidone levels 2.5-fold, and lets you prescribe it in cirrhosis or hepatitis with no dose change when impairment is mild to moderate.
2. It is the only antipsychotic FDA-approved for schizoaffective disorder. The evidence base isn't huge, but the approval is a regulatory distinction that helps when you're documenting.
3. The long-acting injectable family is best-in-class for interval. Invega Sustenna (monthly) needs no oral overlap, and Invega Hafyera doses every six months: two clinic visits a year. Hafyera has rehabilitated the oral generic as a rational stepping-stone.

A Carlat 20-year retrospective gives the more recent view: "Now that paliperidone is available as a six-month injection (Invega Hafyera), I'm more likely to start the oral, generic paliperidone when treating schizophrenia, knowing that the six-month product is out there if we need it."

Part 1: Indications

FDA-Approved Uses

• Schizophrenia (oral ER in adults and adolescents 12–17; the LAIs in adults only)
• Schizoaffective disorder in adults, as monotherapy or adjunct to mood stabilizers/antidepressants. Paliperidone is the only antipsychotic FDA-approved for this indication.

What It Is Not Approved For

Bipolar mania: failed FDA approval. This matters, and people often misremember it. In a network meta-analysis of 42 RCTs (~11,400 patients), paliperidone ranked 3rd for antimanic efficacy (effect size 0.71, behind risperidone 0.82 and haloperidol 0.74). But the registration trials were inconsistent, and the FDA declined approval. If you use it for mania, you are prescribing off-label on a reasonable but non-approved evidence base; the optimal dose is around 9.1 mg/day.

Bipolar depression: off-label, thin data. If you want a metabolically lighter agent for the depressed pole, lurasidone is FDA-approved for bipolar depression and is the better-evidenced choice.

Where Paliperidone Excels

• The patient with liver disease. Cirrhosis, active hepatitis, fatty liver, or on hepatotoxic co-medications: paliperidone needs no dose adjustment in mild-to-moderate impairment because it isn't hepatically metabolized. Severe hepatic impairment was never studied, so stay cautious there.
• The patient on CYP2D6-active polypharmacy. Fluoxetine, paroxetine, duloxetine, bupropion, and quinidine all raise risperidone levels 2.5 to 2.8-fold and would force a dose cut. Paliperidone doesn't budge. If your patient needs fluoxetine for comorbid OCD or depression, paliperidone plus fluoxetine is cleaner than risperidone plus fluoxetine.
• The patient who needs adherence assurance. The LAI franchise (monthly Sustenna, 6-month Hafyera) is the strategic reason to start oral paliperidone at all; it gives you a defined escalation path.
• Schizoaffective disorder, especially the depressed subtype.
• Treatment-resistant schizophrenia after 1 to 2 failed trials (not a clozapine substitute, see Part 10). In a head-to-head RCT it matched olanzapine on symptoms at roughly half the milligram burden and with less waist-circumference gain.

Where Paliperidone Is a Poor Choice

• Acute agitation or severe anxiety. The OROS tablet releases over 24 hours with a peak at ~24 h: smooth, but too slow to quell an acute crisis. Immediate-release risperidone often calms an agitated patient the same day; oral Invega will not.
• Patients who cannot swallow an intact tablet. The OROS shell must stay whole: no crushing, no chewing, no feeding tube. Use an alternative (or an LAI) instead.
• Patients with baseline QT prolongation or high cardiac risk: paliperidone adds ~12 msec and 12 to 14% tachycardia. Prefer aripiprazole, quetiapine, or lurasidone.
• Prolactin-sensitive patients (young women concerned about menstrual/fertility effects; anyone with prior galactorrhea): this is a strong, sustained prolactin raiser.

Part 2: Before You Start: Workup

The standard second-generation antipsychotic baseline, plus two paliperidone-specific checks: an ECG and renal function.

You do not need baseline or routine LFTs for drug-clearance purposes, an advantage over risperidone. (Check them if the patient's medical status otherwise warrants.)

Candidacy Checks

• Can the patient swallow a tablet whole? If not, this drug is off the table (oral).
• Is the eGFR ≥60? If not, the dose ceiling drops sharply (Part 8).
• Any personal/family history of long QT, torsades, or sudden cardiac death? Any QT-prolonging co-meds? If yes, reconsider the agent.

Part 3: How to Start and Dose

Oral Extended-Release (Invega)

• Start: 6 mg once daily. Can be taken with or without food (bioavailability is food-independent, unlike lurasidone). No initial titration is required pharmacologically.
• Do not believe "6 mg and done." Janssen marketed "start and end with 6 mg, no dose adjustment needed." In the two pivotal trials, Invega 6 mg was less effective than olanzapine 10 mg, and researchers had to push Invega to 12 mg to match it.
• Typical effective range: 9 to 12 mg once daily. Titrate in 3 mg steps, no faster than every ~5 days (steady state is reached in ~4 to 5 days given the ~24-hour half-life). A simple schedule: 6 mg for ~5 days, then 9 mg for ~5 days, then 12 mg.
• Maximum: 12 mg/day. But mind the EPS penalty (below).
• Off-label acute mania: optimal dose ~9.1 mg/day.
• Treatment-resistant schizophrenia: effective mean dose ~10.7 mg/day in trial data.

The tablet is an OROS osmotic pump (same technology as Concerta): a rigid shell that pushes drug out through a laser-drilled hole. It must be swallowed whole: do not crush, split, or chew. Patients will sometimes see the empty "ghost" shell in the stool; reassure them the drug was absorbed.

Long-Acting Injectable: Invega Sustenna (Monthly)

Paliperidone palmitate depot. Its characteristic advantage over Risperdal Consta is that it works immediately, with no 3-week oral overlap, because the loading doses front-load exposure.

• Loading (do not skip): 234 mg IM in the deltoid on Day 1, then 156 mg IM on Day 8 (both deltoid). Skipping the load is the classic reason Sustenna "doesn't work."
• Maintenance: 117 mg IM every 4 weeks (deltoid or gluteal), roughly equivalent to ~6 mg oral. Range 39 to 234 mg monthly by response.
• Cost (order of magnitude): loading ~$3,000; maintenance ~$1,000/month. (Risperdal Consta ~$900/month; haloperidol decanoate ~$15/month.)

Long-Acting Injectable: Invega Hafyera (Every 6 Months)

• Every-6-month paliperidone palmitate. Patient must be stabilized on Sustenna (or the 3-month Trinza) first before converting.
• Its strategic value is 2 injections a year, and it is the formulation that makes the whole paliperidone family worth engaging with.
• Tradeoff: less frequent contact means fewer chances to catch early relapse or emerging side effects; reserve for engaged, stable patients.

Invega Trinza (Every 3 Months)

Trinza is the intermediate step between monthly Sustenna and 6-monthly Hafyera. Convert only after the patient has been on Sustenna for at least 4 months with the last two monthly doses the same. The Trinza dose is 3.5× the last monthly Sustenna dose (e.g., Sustenna 117 mg → Trinza 410 mg; 156 mg → 546 mg; 234 mg → 819 mg). Hafyera then follows after ≥4 months of Sustenna or ≥1 Trinza cycle.

Dose Adjustments and Special Populations

• Renal impairment (the defining adjustment, since paliperidone is ~59% renally excreted unchanged): ORAL: CrCl 50–79 mL/min start 3 mg, max 6 mg/day; CrCl 10–49 start 1.5 mg, max 3 mg/day; <10 not recommended. Sustenna: for mild impairment (CrCl 50–79) use the reduced initiation (156 mg day 1, 117 mg day 8) then 78 mg monthly; not recommended for CrCl <50. Trinza and Hafyera are not recommended in renal impairment.
• Hepatic impairment: no adjustment for mild-to-moderate (severe not studied).
• Drug interactions: renally cleared with minimal CYP metabolism, so paliperidone has fewer interactions than parent risperidone, and that counts in its favor; strong inducers (carbamazepine, rifampin) still lower levels.
• Geriatric / dementia: dose to renal function; the class boxed warning applies.
• Pediatric: schizophrenia approved 12–17 (weight-based oral).
• Prolactin: like risperidone, paliperidone markedly raises prolactin (dose-related).

Stopping and Switching

• Discontinuation: taper the oral form; the LAIs self-taper over months given their kinetics, so account for the long tail when switching or managing side effects.

Part 4: Monitoring

Metabolic (Class-Wide)

Paliperidone-Specific

• Prolactin: at baseline, then check when symptomatic: galactorrhea, amenorrhea, gynecomastia, or sexual dysfunction. Elevations are substantial and can persist even after dose reduction.
• Renal function (creatinine/eGFR): baseline and periodically (annually if stable; sooner if renal status changes), because clearance and your dose ceiling depend on it.
• ECG / QTc: baseline for everyone; repeat if the dose reaches 12 mg, cardiac or QT risk factors, QT-prolonging co-medication, or new cardiac symptoms. Routine serial ECGs are not required in low-risk patients.
• Heart rate: check at visits; tachycardia runs 12 to 14% against 7% on placebo, above the 2 to 5% reported in risperidone's adult trials.
• LFTs: not needed for the drug.

Sustenna post-injection: unlike olanzapine (Zyprexa Relprevv), paliperidone LAIs do not carry a post-injection delirium/sedation syndrome and do not require the 3-hour observation window.

Part 5: Side Effects and How to Manage Them

Paliperidone's side effects are dose-dependent (EPS, prolactin, QT all climb with the milligrams) and mostly manageable, but the dose you need for efficacy is the dose that produces them, so manage them proactively.

Extrapyramidal Symptoms (EPS)

Parkinsonism (tremor, rigidity, bradykinesia), acute dystonia, and akathisia. Incidence ~10% at 6 mg to ~26% at 12 mg. Dystonia in particular is more common with paliperidone/risperidone than with many peers.

Management, in order:

1. Reduce the dose if clinically feasible: the single most effective move.
2. Acute dystonia (oculogyric crisis, torticollis, laryngospasm): benztropine 1 to 2 mg IM/IV STAT, resolves in 5 to 30 minutes. This is an emergency; treat first, ask later.
3. Parkinsonism: anticholinergic, benztropine 0.5 to 2 mg BID or trihexyphenidyl 2 to 5 mg BID; or amantadine 100 mg BID; it lowers prolactin too.
4. Akathisia: propranolol is first-line and beats anticholinergics here. Start around 10 mg BID and titrate to response; trials used 20 to 120 mg/day. Add a benzodiazepine (clonazepam from 0.5 mg, titrated slowly) if needed. Anticholinergics alone don't help akathisia.

Hyperprolactinemia and Sexual Dysfunction

Paliperidone is a strong, sustained prolactin raiser (the depot may sustain it even more than oral). Sexual dysfunction affects 40 to 70% of antipsychotic patients and is worse with the prolactin-raisers: paliperidone, risperidone, haloperidol. Also seen: galactorrhea, amenorrhea, gynecomastia; long-term, hypogonadism and bone-density concerns.

Management (dose reduction often fails with this drug):

• Amantadine 100 mg BID: dopamine agonist, pulls prolactin down; may also aid weight.
• Add low-dose aripiprazole 5 to 15 mg/day: a partial D2 agonist that reliably lowers antipsychotic-induced prolactin and may help negative symptoms/cognition. This is the most effective add-on strategy.
• For the sexual symptom itself: a PDE5 inhibitor (sildenafil, tadalafil) helps both sexes.
• Switch to a prolactin-sparing agent: aripiprazole, brexpiprazole, ziprasidone, or quetiapine. If prolactin is the dealbreaker, this is often the cleanest answer.

Cardiac

• QT prolongation ~12 msec above placebo (similar to ziprasidone's ~10 msec). Clinically modest, but avoid in baseline QT prolongation, personal/family history of torsades or sudden cardiac death, or when stacking QT-prolonging drugs. Watch macrolides, azole antifungals, and some antiretrovirals.
• Tachycardia 12 to 14%: usually benign; check pulse, reassure, address contributing orthostasis.
• Orthostatic hypotension: less than some atypicals, but real. Check lying/standing BP early, counsel slow position changes.

Weight Gain and Metabolic Effects

Moderate, comparable to risperidone, less than olanzapine or clozapine. In the treatment-resistant trial, olanzapine produced significantly more waist-circumference gain (p=0.030).

Management:

• Lifestyle counseling; monitor weight, glucose, lipids on the schedule above.
• Metformin: start 500 mg BID, titrate toward 1,000 mg BID (~750 mg/day is enough for benefit in some protocols). Expect ~3 to 4 kg less weight gain when started concurrently with the antipsychotic. Well tolerated (mainly GI); check eGFR before starting and periodically after, and vitamin B12 on long-term use. Start it early in patients with cardiometabolic risk or >3% weight gain in the first month.

Other Common Effects

• Somnolence: dose-dependent; dose at bedtime, or reduce.
• Nausea: usually early and self-limited; take with food.

Tardive Dyskinesia

Atypicals carry roughly 1%/year cumulative TD risk (vs ~5%/year with first-generation agents), but paliperidone does cause it. Risk climbs with age (up to ~10-fold higher in middle-aged/elderly after a year), duration, and cumulative dose.

Management:

• Prevent: lowest effective dose; screen at visits for lip-smacking, tongue movements, choreoathetoid finger/limb movements (AIMS exam).
• If TD develops: a VMAT2 inhibitor is first-line: valbenazine or deutetrabenazine (both FDA-approved for TD). (Older dopamine-depleters like tetrabenazine and reserpine are off-label and less tolerable: depression, orthostasis, akathisia.) Reduce/switch the offending antipsychotic slowly; abrupt withdrawal can transiently worsen TD. Do not add anticholinergics.

Part 6: Toxicity and Boxed Warnings

Neuroleptic Malignant Syndrome (NMS)

Rare, life-threatening: fever, lead-pipe rigidity, altered mental status, autonomic instability (labile BP, tachycardia, diaphoresis), with elevated CK. Management: stop the antipsychotic immediately; ED-level supportive care (aggressive cooling, IV fluids, monitoring); dantrolene and/or bromocriptine for severe cases. Restart any antipsychotic only cautiously, later, with a different agent.

Overdose

No paliperidone-specific antidote; expect sedation, EPS, QT prolongation, hypotension. Supportive care, continuous ECG monitoring, electrolyte correction, activated charcoal only if very early.

Other Safety Notes

• Seizure threshold: lowered modestly (as with all antipsychotics); caution in seizure history.
• The "cheeking" quirk: because the OROS tablet stays intact, a non-adherent patient can hide it in the cheek and spit it out more easily than crushed risperidone mixed in food. Helpful for detecting non-adherence under supervision; a liability for covert dosing.

Part 7: Drug Interactions

The interaction profile is paliperidone's best feature and the reason the molecule exists. Paliperidone undergoes minimal hepatic metabolism and is largely renally excreted (about 80% recovered in urine, roughly 59% of the dose unchanged) with no single dominant CYP450 pathway, so it has almost no clinically significant CYP450 drug interactions.

The interactions that do matter for paliperidone are pharmacodynamic, not pharmacokinetic:

• QT-prolonging drugs (macrolides, azole antifungals, class IA/III antiarrhythmics, other QT-prolonging antipsychotics): additive QT risk; avoid stacking.
• CNS depressants / alcohol: additive sedation.
• Antihypertensives: additive orthostasis.
• Strong inducers: carbamazepine lowered steady-state paliperidone Cmax and AUC by about 37% in the labeled interaction study, probably through P-glycoprotein induction. Re-evaluate the paliperidone dose when carbamazepine or another strong inducer starts, and again when it stops.

Part 8: Special Populations

Renal Impairment

Because paliperidone is renally cleared, kidney function sets the ceiling. Approximate framework:

Monitor creatinine/eGFR at baseline and periodically; re-evaluate the dose whenever renal function shifts. LAIs are generally not recommended below CrCl 50 because you cannot retrieve a depot if function declines.

Hepatic Impairment

No dose adjustment needed in mild-to-moderate hepatic impairment. Severe hepatic impairment has not been studied, so stay cautious there. The absence of a hepatic adjustment across most of the range is paliperidone's characteristic advantage and the reason to reach for it over risperidone in liver disease.

Elderly

• Age-related renal decline (CrCl can fall ~50% by 80) is what drives dosing here: about 59% of the dose leaves unchanged in urine, so clearance falls with the kidneys and paliperidone accumulates.
• Start low (3 mg), titrate slowly (every 2 to 4 weeks, not weekly). Track renal function closely; adjust for CrCl <60.
• Heightened vulnerability to falls (orthostasis, sedation, EPS), TD (up to ~10-fold), stroke/mortality in dementia (boxed warning), and hyponatremia/SIADH (check sodium if new confusion). Consider fall precautions and PT/OT.

Pregnancy

• Untreated psychosis carries substantial risk to mother and fetus; for many patients continuing an antipsychotic is the safer path. Decide collaboratively with perinatal psychiatry and OB.
• Paliperidone crosses the placenta. Third-trimester exposure risks neonatal EPS and withdrawal (abnormal tone, feeding difficulty, tremor, agitation), a class effect flagged by the FDA; arrange neonatal monitoring.
• Associated signals: possible gestational diabetes, weight gain, and limited/mixed preterm-birth data.
• LAIs complicate pregnancy management (you cannot dose-adjust a depot quickly); oral is more flexible if changes are anticipated.

Lactation

Excreted into breast milk (roughly ~1 to 10% of maternal plasma levels). Infant sedation/EPS risk is low but possible. If the mother chooses to breastfeed, monitor the infant for excess sedation, poor feeding, and tremor, in coordination with pediatrics.

Pediatrics / Adolescents

Oral Invega is FDA-approved for schizophrenia in adolescents 12 to 17. The schizoaffective indication is adults only, and so are the injectables. Dose lower than adults, often weight-informed. EPS, metabolic effects, and prolactin elevation all apply: weight gain and prolactin are especially concerning in teens. Wrap treatment in psychosocial support, family involvement, and school coordination.

Part 9: Discontinuation

Antipsychotics should be tapered, not stopped abruptly.

How to Taper

• Reduce by ~10 to 25% every 1 to 2 weeks (over ~4 to 8 weeks for oral), monitoring for rebound psychosis, akathisia, and emergent dyskinesia.
• Schizophrenia: maintenance is generally long-term/lifelong; relapse risk on discontinuation is high. Don't taper without a compelling reason and a follow-up plan.
• Schizoaffective disorder: long-term, guided by mood stability.
• Bipolar (off-label): continue ~6 to 12 months past mood stabilization, then a slow taper (1 to 2 months) is optional if indicated.

LAI note: with Sustenna and especially Hafyera, the depot self-tapers over weeks to months; relapse, if it comes, is delayed. That's protective if a patient misses an appointment, but it also means you can't quickly reverse course; plan discontinuations accordingly.

Part 10: Paliperidone vs the Alternatives

No head-to-head trial exists between paliperidone and risperidone. Default to generic risperidone unless a paliperidone-specific reason applies.

For the depressed pole or metabolic concerns, choose lurasidone; for schizoaffective disorder, liver disease, or CYP2D6 interactions, choose paliperidone.

Mechanism

Paliperidone is 9-hydroxyrisperidone, risperidone's active metabolite. Like other second-generation agents it is a D2 dopamine antagonist (antipsychotic effect) and 5-HT2A serotonin antagonist (the serotonin blockade loosens the dopamine blockade in nigrostriatal pathways, buying lower EPS than first-generation drugs, though paliperidone's EPS still climbs with dose). It has relatively low affinity for histamine H1, muscarinic M1, and alpha-1 receptors versus olanzapine/clozapine, hence less sedation, fewer anticholinergic effects, and less weight gain than those two, but also little sedative cover. Its high D2 potency in the tuberoinfundibular pathway explains the marked prolactin elevation.

Pharmacokinetics that define its clinical behavior:

• Half-life ~23 to 24 hours, allowing once-daily oral dosing; steady state in ~4 to 5 days.
• OROS extended release, Tmax ~24 hours: smooth levels, but too slow for acute agitation.
• Largely renal excretion (~80% in urine, ~59% unchanged), minimal hepatic metabolism: almost no CYP interactions, no hepatic dose change in mild-to-moderate impairment, renally dose-limited.
• Palmitate ester depot (Sustenna/Hafyera) dissolves slowly for 4-week or 6-month release.

Bedside Cheat Sheet